DMAC logo

DiaMedica Therapeutics (DMAC) Cash From Financing

Annual CFF

$36.84 M
+$36.85 M+614133.33%

December 31, 2023

Summary

Performance

1-Year Change

+614133.33%

3-Year Change

+27.72%

5-Year Change

+73.65%

15-Year Change

+941.03%

DMAC Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

75.12%
DMAC annual cash flow from financing activities is higher than 75.12% of companies in Healthcare sector

High & Low

All-time High

$36.84 M
DMAC annual cash flow from financing activities is currently at an all-time high

3-Year Low

-$6000.00

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2023
DMAC previous annual earnings announcement was published on Dec 31, 2023

Next Annual Earnings Report Date

Mar 20, 2025
DMAC next annual earnings announcement is scheduled for Mar 20, 2025

OtherDMACcash flowmetrics:

Annual CFI

-$18.30 M
DMAC annual cash flow from investing activities is -$18.30 million

Annual CFO

-$18.73 M
DMAC annual cash flow from operations is -$18.73 million

Annual FCF

-$18.75 M
DMAC annual free cash flow is -$18.75 million

Annual CAPEX

-
DMAC annual capital expenditures value is unknown

Quarterly CFF

$123.00 K
-$11.63 M-98.95%

September 30, 2024

Summary

Performance

3-Month Change

-98.95%

1-Year Change

+2150%

3-Year Change

-99.59%

5-Year Change

-99.59%

DMAC Quarterly CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

52.71%
DMAC quarterly cash flow from financing activities is higher than 52.71% of companies in Healthcare sector

High & Low

All-time High

$36.85 M
DMAC quarterly cash flow from financing activities is currently -99.67% below its historical high of $36.85 million

3-Year Low

-$19.00 K

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
DMAC previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Mar 20, 2025
DMAC next earnings announcement is scheduled for Mar 20, 2025

OtherDMACcash flowmetrics:

Quarterly CFI

-$5.58 M
DMAC quarterly cash flow from investing activities is -$5.58 million

Quarterly CFO

-$4.47 M
DMAC quarterly cash flow from operations is -$4.47 million

Quarterly FCF

-$4.48 M
DMAC quarterly free cash flow is -$4.48 million

Quarterly CAPEX

-
DMAC quarterly capital expenditures value is unknown

TTM CFF

$11.87 M
+$129.00 K+1.10%

September 30, 2024

Summary

Performance

3-Month Change

+1.1%

1-Year Change

-67.77%

3-Year Change

-60.51%

5-Year Change

-60.51%

DMAC TTM CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

56.57%
DMAC TTM cash flow from financing activities is higher than 56.57% of companies in Healthcare sector

High & Low

All-time High

$36.85 M
DMAC TTM cash flow from financing activities is currently -67.78% below its historical high of $36.85 million

3-Year Low

-$24.00 K

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
DMAC previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Mar 20, 2025
DMAC next earnings announcement is scheduled for Mar 20, 2025

OtherDMACcash flowmetrics:

TTM CFI

$9.48 M
DMAC TTM cash flow from investing activities is $9.48 million

TTM CFO

-$19.45 M
DMAC TTM cash flow from operations is -$19.45 million

TTM FCF

-$19.48 M
DMAC TTM free cash flow is -$19.48 million

TTM CAPEX

-
DMAC TTM capital expenditures value is unknown

Cash From Financing Formula

CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities

DMAC Cash From Financing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+10000.0%+2150.0%-67.8%
3 y3 years+27.7%-99.6%-60.5%
5 y5 years+73.7%-99.6%-60.5%

DMAC Cash From Financing Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high>+9999.0%-99.7%+747.4%-67.8%>+9999.0%
5 y5-yearat high>+9999.0%-99.7%+415.4%-67.8%>+9999.0%
alltimeall timeat high>+9999.0%-99.7%+170.3%-67.8%+6880.7%

DiaMedica Therapeutics Cash From Financing History

DateAnnualQuarterlyTTM
Sep 2024
-
$123.00 K(-99.0%)
$11.87 M(+1.1%)
Jun 2024
-
$11.75 M(<-9900.0%)
$11.74 M(-68.1%)
Mar 2024
-
-$1000.00(0.0%)
$36.84 M(0.0%)
Dec 2023
$36.84 M(<-9900.0%)
-$1000.00(-83.3%)
$36.84 M(0.0%)
Sep 2023
-
-$6000.00(-100.0%)
$36.84 M(-0.0%)
Jun 2023
-
$36.85 M(<-9900.0%)
$36.85 M(<-9900.0%)
Mar 2023
-
-$1000.00(0.0%)
-$6000.00(0.0%)
Dec 2022
-$6000.00(-100.0%)
-$1000.00(-50.0%)
-$6000.00(-75.0%)
Sep 2022
-
-$2000.00(0.0%)
-$24.00 K(-100.1%)
Jun 2022
-
-$2000.00(+100.0%)
$29.84 M(-0.0%)
Mar 2022
-
-$1000.00(-94.7%)
$29.84 M(-0.8%)
Dec 2021
$30.09 M(+4.3%)
-$19.00 K(-100.1%)
$30.09 M(+0.1%)
Sep 2021
-
$29.86 M(<-9900.0%)
$30.07 M(+40.6%)
Jun 2021
-
-$1000.00(-100.4%)
$21.39 M(0.0%)
Mar 2021
-
$242.00 K(-720.5%)
$21.39 M(-25.8%)
Dec 2020
$28.84 M(>+9900.0%)
-$39.00 K(-100.2%)
$28.84 M(-0.1%)
Sep 2020
-
$21.19 M(<-9900.0%)
$28.88 M(+275.4%)
Jun 2020
-
-$1000.00(-100.0%)
$7.69 M(-1.0%)
Mar 2020
-
$7.70 M(<-9900.0%)
$7.77 M(>+9900.0%)
Dec 2019
$70.00 K(-99.7%)
-$1000.00(0.0%)
$70.00 K(-99.5%)
Sep 2019
-
-$1000.00(-101.4%)
$14.88 M(-0.2%)
Jun 2019
-
$74.00 K(-3800.0%)
$14.91 M(+0.2%)
Mar 2019
-
-$2000.00(-100.0%)
$14.89 M(-29.8%)
Dec 2018
$21.22 M(+499.5%)
$14.81 M(>+9900.0%)
$21.22 M(+166.8%)
Sep 2018
-
$31.00 K(-36.7%)
$7.95 M(+0.4%)
Jun 2018
-
$49.00 K(-99.2%)
$7.92 M(-19.6%)
Mar 2018
-
$6.32 M(+308.2%)
$9.86 M(+178.5%)
Dec 2017
$3.54 M(-22.5%)
$1.55 M(>+9900.0%)
$3.54 M(+79.6%)
Sep 2017
-
$0.00(-100.0%)
$1.97 M(-64.7%)
Jun 2017
-
$1.98 M(>+9900.0%)
$5.58 M(+37.7%)
Mar 2017
-
$6700.00(-135.1%)
$4.05 M(-11.3%)
Dec 2016
$4.56 M(+203.3%)
-$19.10 K(-100.5%)
$4.56 M(-10.5%)
Sep 2016
-
$3.61 M(+687.8%)
$5.10 M(+270.9%)
Jun 2016
-
$457.60 K(-12.1%)
$1.38 M(-14.2%)
Mar 2016
-
$520.50 K(+0.5%)
$1.60 M(+6.5%)
Dec 2015
$1.50 M
$517.70 K(-529.6%)
$1.50 M(+63.6%)
DateAnnualQuarterlyTTM
Sep 2015
-
-$120.50 K(-117.6%)
$919.80 K(-64.3%)
Jun 2015
-
$684.90 K(+62.1%)
$2.58 M(+35.6%)
Mar 2015
-
$422.60 K(-728.9%)
$1.90 M(+13.3%)
Dec 2014
$1.68 M(-71.9%)
-$67.20 K(-104.4%)
$1.68 M(-55.3%)
Sep 2014
-
$1.54 M(>+9900.0%)
$3.75 M(+62.2%)
Jun 2014
-
$7200.00(-96.4%)
$2.31 M(+4.2%)
Mar 2014
-
$198.80 K(-90.1%)
$2.22 M(-62.8%)
Dec 2013
$5.97 M(+15.6%)
$2.01 M(+1910.9%)
$5.97 M(+52.8%)
Sep 2013
-
$99.80 K(-215.5%)
$3.91 M(-30.9%)
Jun 2013
-
-$86.40 K(-102.2%)
$5.66 M(-37.6%)
Mar 2013
-
$3.95 M(-7220.2%)
$9.07 M(+75.5%)
Dec 2012
$5.17 M(+52.4%)
-$55.50 K(-103.0%)
$5.17 M(-2.1%)
Sep 2012
-
$1.85 M(-44.5%)
$5.28 M(-19.3%)
Jun 2012
-
$3.32 M(+6535.5%)
$6.54 M(+98.8%)
Mar 2012
-
$50.10 K(-8.1%)
$3.29 M(-2.9%)
Dec 2011
$3.39 M(-26.5%)
$54.50 K(-98.2%)
$3.39 M(-45.5%)
Sep 2011
-
$3.11 M(+4081.3%)
$6.21 M(+103.4%)
Jun 2011
-
$74.40 K(-49.9%)
$3.05 M(-35.8%)
Mar 2011
-
$148.60 K(-94.8%)
$4.76 M(+3.2%)
Dec 2010
$4.61 M(>+9900.0%)
$2.88 M(-6061.5%)
$4.61 M(+166.2%)
Sep 2010
-
-$48.30 K(-102.7%)
$1.73 M(-2.7%)
Jun 2010
-
$1.78 M(>+9900.0%)
$1.78 M(>+9900.0%)
Mar 2010
-
$0.00(0.0%)
$0.00(0.0%)
Dec 2009
$0.00(-100.0%)
$0.00(0.0%)
$0.00(-100.0%)
Sep 2009
-
$0.00(0.0%)
-$175.10 K(-115.0%)
Jun 2009
-
$0.00(-100.0%)
$1.17 M(0.0%)
Dec 2008
$1.17 M(-75.1%)
-$175.10 K(-113.0%)
$1.17 M(-13.3%)
Sep 2008
-
$1.35 M(>+9900.0%)
$1.35 M(+149.0%)
Mar 2008
-
$0.00(-100.0%)
$542.30 K(-88.4%)
Dec 2007
$4.69 M(+418.1%)
$5100.00(-98.3%)
$4.69 M(+0.1%)
Sep 2007
-
$294.50 K(+21.3%)
$4.69 M(+6.7%)
Jun 2007
-
$242.70 K(-94.2%)
$4.39 M(+5.8%)
Mar 2007
-
$4.15 M
$4.15 M
Dec 2006
$905.90 K(-22.9%)
-
-
Dec 2005
$1.18 M(+636.7%)
-
-
Dec 2004
$159.50 K
-
-

FAQ

  • What is DiaMedica Therapeutics annual cash flow from financing activities?
  • What is the all time high annual CFF for DiaMedica Therapeutics?
  • What is DiaMedica Therapeutics annual CFF year-on-year change?
  • What is DiaMedica Therapeutics quarterly cash flow from financing activities?
  • What is the all time high quarterly CFF for DiaMedica Therapeutics?
  • What is DiaMedica Therapeutics quarterly CFF year-on-year change?
  • What is DiaMedica Therapeutics TTM cash flow from financing activities?
  • What is the all time high TTM CFF for DiaMedica Therapeutics?
  • What is DiaMedica Therapeutics TTM CFF year-on-year change?

What is DiaMedica Therapeutics annual cash flow from financing activities?

The current annual CFF of DMAC is $36.84 M

What is the all time high annual CFF for DiaMedica Therapeutics?

DiaMedica Therapeutics all-time high annual cash flow from financing activities is $36.84 M

What is DiaMedica Therapeutics annual CFF year-on-year change?

Over the past year, DMAC annual cash flow from financing activities has changed by +$36.85 M (+614133.33%)

What is DiaMedica Therapeutics quarterly cash flow from financing activities?

The current quarterly CFF of DMAC is $123.00 K

What is the all time high quarterly CFF for DiaMedica Therapeutics?

DiaMedica Therapeutics all-time high quarterly cash flow from financing activities is $36.85 M

What is DiaMedica Therapeutics quarterly CFF year-on-year change?

Over the past year, DMAC quarterly cash flow from financing activities has changed by +$129.00 K (+2150.00%)

What is DiaMedica Therapeutics TTM cash flow from financing activities?

The current TTM CFF of DMAC is $11.87 M

What is the all time high TTM CFF for DiaMedica Therapeutics?

DiaMedica Therapeutics all-time high TTM cash flow from financing activities is $36.85 M

What is DiaMedica Therapeutics TTM CFF year-on-year change?

Over the past year, DMAC TTM cash flow from financing activities has changed by -$24.97 M (-67.77%)